Quest Diagnostics Inc. (DGX)
Quest Diagnostics' (DGX) New Study Exposes Alarming Data on STI
Quest Diagnostics' (DGX) joint study with the University of Alabama finds pregnant women undertested for STIs, raising serious concerns on maternal and newborn health.
Should Value Investors Buy Quest Diagnostics (DGX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Quest Diagnostics (DGX) Gains From Innovation, Customer Wins
A key driver in Brain Health growth is Quest Diagnostics' (DGX) Alzheimer's disease portfolio, featuring the AD-Detect blood testing services and the CSF Tests for diagnosing and monitoring.
Should Quest Diagnostics (DGX) be in Your Portfolio Now?
Quest Diagnostics' (DGX) robust base business performance instills optimism for long-term growth.
Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
DGX vs. PNTG: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Quest Diagnostics (DGX) or The Pennant Group, Inc. (PNTG). But which of these two stocks is more attractive to value investors?
Are Investors Undervaluing Quest Diagnostics (DGX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Quest Diagnostics: Beat Down After Beating Q2 Estimates
Quest Diagnostics: Beat Down After Beating Q2 Estimates
Quest Diagnostics' (DGX) Haystack Oncology Forges New MRD Deal
Quest Diagnostics' (DGX) subsidiary, Haystack Oncology, partners on the use of its MRD technology.
Quest Diagnostics' Q2 Earnings Performance Suggests Stable Stock, Modest Growth Ahead, Analyst Says
On Tuesday, Quest Diagnostics Inc DGX posted second-quarter adjusted EPS of $2.35, beating the consensus of $2.34.
Quest Diagnostics Incorporated (DGX) Q2 2024 Earnings Call Transcript
Quest Diagnostics Incorporated (NYSE:DGX ) Q2 2024 Earnings Conference Call July 23, 2024 8:30 AM ET Company Participants Jim Davis - Chairman, Chief Executive Officer, President Sam Samad - Chief Financial Officer Shawn Bevec - Vice President of Investor Relations Conference Call Participants Ann Hynes - Mizuho Securities Kevin Caliendo - UBS Michael Cherny - Leerink Patrick Donnelly - Citi David Westenberg - Piper Sandler Erin Wright - Morgan Stanley Brian Tanquilut - Jeffries Lisa Gill - JP Morgan Michael Ryskin - Bank of America Jack Meehan - Nephron Research Andrew Brackmann - William Blair Pito Chickering - Deutsche Bank Stephanie Davis - Barclays Operator Welcome to the Quest Diagnostics Second Quarter 2024 conference call. At the request of the company, this call is being recorded.
Quest Diagnostics (DGX) Tops Q2 Earnings, Raises 2024 Outlook
Quest Diagnostics (DGX) delivers impressive base business growth in the second quarter of 2024.
